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Expression of PD-L1 in tumor and 
immune system cells affects the survival 
of patients with urinary bladder cancer
ABSTRACT
Background: The prediction of tumor malignancy is still one of the most demanding diagnostic tasks 
in urinary bladder cancer because of its clinicopathological heterogeneity. The aim of this study was to 
evaluate the expression of PD-L1 in tumor cells (TCs) and immune effector cells (IECs) as well as the 
pattern of distribution of PD-L1+ IECs within the tumor (dispersed or aggregated) and their association 
with survival of patients with pT1-pT4 urinary bladder cancer.
Materials and methods: 110 patients with stage pT1-pT4 urothelial bladder carcinoma who underwent 
radical cystectomy/cystoprostatectomy between 2011 and 2014 were included in the study. Paraffin blocks 
most representative of the tumor were selected for H&E staining as well as immunostaining with the use 
of rabbit anti-PD-L1 (Ventana clone SP142, Roche). In each sample, the area of the tumor containing PD-
L1+ IECs, as well as, the pattern of distribution (dispersed or aggregated) of PD-L1+ immune effector 
cells within the tumor were analyzed. In addition, the expression of PD-L1 in TCs was also assessed.
Results: Patients had a shorter survival time in pT2-pT4 cases without TCs expressing PD-L1 (p = 0.007) 
and/or when PD-L1+ IECs displayed a predominantly dispersed pattern of distribution (p = 0.013).
Conclusions: The expression of PD-L1 on TCs and IECs is a prognostic factor which allows for stratifica-
tion of patient survival in UBC. The predominance of dispersed or aggregated pattern of distribution of 
PD-L1+ IECs in the tumor may be considered as a new prognostic factor in pT1-T4 UBC and indicate the 
functional status of the immune system.
Key words: PD-L1; urothelial bladder cancer; tumor microenvironment; immune cell distribution, immune 
effector cells, immune checkpoint inhibitors
Med Res J 2019; 4 (3): 142–147
Corresponding author: 
Wojciech Jóźwicki, Department  
of Tumor Pathology  
and Pathomorphology, Oncology 
Centre-Prof. Franciszek Łukaszczyk 
Memorial Hospital,  
Bydgoszcz 85-796,  
Romanowskiej 2 St., Poland,  
e-mail: jozwickiw@co.bydgoszcz.pl
Medical Research Journal 2019;
Volume 4, Number 3, 142–147
10.5603/MRJ.a2019.0026
Copyright © 2019 Via Medica
ISSN 2451–2591
Introduction
Urothelial bladder cancer (UBC) is the seventh 
most frequency occurring cancers in men and may be 
responsible for 200 000 deaths in 2018 [1]. The assess-
ment of the tumor malignancy requires the assessment 
of tumor advancement (pT), histological malignancy 
(G), number of nonclassic differentiation types (NDN) 
and the tissue invasion type (TIT) [2–4]. Unfortunately, 
the prediction of the tumor progression and the risk of 
recurrence remains a diagnostic and therapeutic chal-
lenge in UBC. Its histological and clinical heterogeneity 
which likely reflects its molecular heterogeneity makes 
understanding the biological mechanisms of UBC ma-
lignancy a challenging area of research [5–8]. Recent 
studies have indicated several probable mechanisms 
of tumor progression by the way of modulating the 
immune system anti-tumor response. One important 
mechanism is the suppression of anti-tumor response 
by an excess infiltration of regulatory T cells (Tregs) 
[9]. The over-expression of RCAS1 in tumor cells (TCs) 
and the surrounding cells of the cancer microenviron-
ment were also shown to correlate with clinical and 
pathomorphological patterns of malignancy [5]. An 
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interesting new area of research is the cancer immune 
evasion through activation of immune checkpoints 
which suppress IECs [10,11]. One such mechanism is 
the PD-1/PD-L1 signalling pathway which suppresses 
the activity of T lymphocytes particularly in the effector 
phase of the immune response [11]. In 2017, Xingyuan 
et al. performed studies that showed the ability of UBC 
TCs to induce immunosuppression in patients through 
upregulation of PD-L1 expression on tumor-associated 
macrophages (TAMs) with the involvement of IL-10 [12]. 
Furthermore, PD-L1 can be expressed in both TCs 
and IECs. There is evidence that its expression within 
the tumor may in some circumstances facilitate the 
escape from immune surveillance and lead to tumor 
progression [10, 13]. The results of clinical trials have 
demonstrated a significant correlation between PD-
L1 expression in some tumors and the effectiveness 
of treatment using immune checkpoint inhibitors (ICI) 
[14–19], especially in early stages of the disease [20], 
and in combination therapies [21]. However, some pa-
tients who meet the criteria for therapy do not respond 
well to anti-PD-L1 treatment [22, 23]. Thus, finding 
new eligibility criteria for immunotherapy to increase its 
efficacy and safety is paramount. The aim of this study 
is to assess the expression of PD-L1 on TCs and IECs 
which are present in the tumor area and to analyze the 
effect of PD-L1 expression on patient survival in UBC.
Materials and methods
A total of 110 patients with pT1-pT4 UBC from On-
cology Centre Prof. Franciszek Łukaszczyk Memorial 
Hospital in Bydgoszcz (Poland) who underwent radical 
cystectomy (or cystoprostatectomy) in 2011–2014 were 
enrolled in this study. The average follow-up time after 
surgery was about 22 months. The clinico-pathologi-
cal characteristics of the study group is presented in 
Table 1.
Staging and histological type of tumors were 
assessed according to the WHO classification [24]. 
Survival data were collected from the National Health 
Fund. The study was approved by the Committee of 
Ethics of Scientific Research of Collegium Medicum, 
Nicolaus Copernicus University, Poland (KB 587/2018).
The preparation and evaluation of H&E stained 
samples
Tissue sections were fixed in 10% buffered formalin 
and embedded in paraffin blocks according to a stan-
dard protocol. The evaluation of HE (Hematoxylin-Eo-
sin) stained sections from each urinary bladder was 
performed and one representative paraffin-embedded 
block was chosen for immunohistochemical staining. 
Table 1. Patient clinico-pathological characteristics
Patient’s characteristics Number of patients
Age (years)
    30–50
    51–60
    61–70
    71–80
    81–90
2
24
53
29
2
Sex
    Female
    Male
22
88
pT
    1
    2a
    2b
    3a
    3b
    4a
    4b
12
13
12
10
31
32
0
pN
    Not available
    0
    1
    2
    3
2
61
12
33
2
Recurrence
    Yes
    No
16
94
Immunohistochemical staining and evaluation of 
samples
Immunohistochemical staining of 4 µm sections was 
performed with rabbit monoclonal anti-PD-L1 (Ventana 
clone SP142, Roche) and visualization system OptiV-
iew DAB IHC Detection Kit and OptiViewAmplification 
Kit using VENTANA BenchMark system, according to 
the manufacturer’s protocol. To confirm the specificity 
of the signal, the same protocol but without the use 
of anti-PD-L1 was performed as a negative control for 
each sample. For each staining cycle, a positive con-
trol sample of human tonsil was included following the 
manufacturer’s recommendations. In each test sample, 
the percentage of tumor area occupied by tumor-asso-
ciated immune cells exhibiting PD-L1 positive staining 
was assessed, regardless of staining intensity or the 
number of ICs present [25] (Fig. 1A, B). Furthermore, 
the pattern of distribution of PD-L1+ IECs in the tumor 
was evaluated as either dispersed or aggregated (with 
cell aggregates of 10 cells or more in a high-power field 
of view) (Fig. 1C, D).
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Figure 1. The panel gives an example of the extent of the presence of PD-L1+ IECs in the tumor: < 5% (A) and ≥ 5% (B). 
The aggregated and dispersed presence of PD-L1+ IECs is shown in figures C and D, respectively. Arrows point to 
immune cells
Figure 2. The picture shows sample images of the presence of PD-L1 expression in tumor cells (A) and its absence (B)
The presence or absence of PD-L1 expression was 
evaluated in the TCs regardless of the intensity and 
extent of the expression.
The microscopic assessment was performed with 
the use of Nikon Eclipse 80i microscope. Pictures were 
taken with Nikon Digital Sight DS Fi1-U2 camera and 
with NISElements BR 3.0 software (Nikon Instruments 
Europe B.V., Badhoevedorp, The Netherlands).
Statistical analysis
The relationship between PD-L1 expression in TCs 
and IECs was analyzed using T-test for independent sam-
ples. PD-L1 expression in TCs and IECs and the probability 
of survival was assessed with Kaplan–Meier curves. The 
statistical analyses were performed using STATISTICA data 
analysis software (version 8.0; StatSoft, Inc., Tulsa, OK, 
USA). A p-value < 0.05 was considered to be significant.
Results
Expression of PD-L1 and survival
The analysis of PD-L1 expression in TCs showed 
that the probability of survival was higher in cases where 
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Discussion
Immune mechanisms play a key role in tumor 
development and progression. Inhibition of anti-tu-
mour response of the immune system and induction 
of immune tolerance are observed in the early and 
late stage of UBC development, respectively [5, 9, 
26–28]. Recent studies have focused on immune 
checkpoint modulation of IECs activity by means of 
a PD1-PDL1 signalling pathway in UBC [11, 29]. We 
have demonstrated that the expression of PD-L1 in 
TCs of UBC is associated with a higher probability of 
survival (Fig. 3). Contrary findings were obtained by 
Chun-Te et al. and also by Yide et al. [30, 31]. However, 
the results of several other authors are not in accord. 
Bellmunt et al. and Davickai et al. confirmed such 
relation in patients with UBC [32, 33], likewise, Kim et 
al. detected an association in head and neck tumors 
[34]. We cannot rule out that the difference in findings 
may be due to an adopted selection of samples (i.e. 
non-epithelial bladder cancer included) and due to 
differences in methodology (a type of antibody, repre-
sentative section sampling). Some other authors report 
that the expression of PD-L1 on TCs may be associated 
with the increase of PD-L1+ IECs numbers within the 
tumor [31]. In our study, we have observed that the 
increase of the extent of the tumor with PD-L1+ IECs is 
associated with the increase of PD-L1 expression in TCs 
(Fig. 5). This may suggest a similar or even synergistic 
involvement of these two cellular components (TCs 
and IECs) in downregulation of anti-tumor response 
through PD-L1. There is no clear consensus on that 
matter in literature [35, 36]. The studies on the role of 
PD-L1 molecule in ovarian cancer demonstrated that 
PD-L1 expression in tumor infiltrating macrophages 
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Figure 3. The survival probability 20 and 50 months after 
cystectomy for UBC was about two and a half times and twice 
higher, respectively, in patients with tumor PD-L1 expression
Figure 4. The probability of survival 4 years after 
cystectomy for UBC was more than twice lower in patients 
with the advantage of dispersed PD-L1+ IECs in tumor
TCs expressed PD-L1 compared to those where such 
expression was not found (Fig. 3).
Further, we observed that the presence of PD-L1+ 
IECs with a dispersed distribution pattern (n = 40) was 
associated with significantly lower survival probability 
(Fig. 4).
Expression of PDL1 in tumor and immune cells 
We observed a strong correlation between the extent 
of PD-L1 expression in TCs and the extent of expression 
of PD-L1 in IECs in close vicinity (p < 0.05; r = 0.60; 
n = 110). The extent of PD-L1 expression in TCs was 
particularly high in tumors where PD-L1+ IECs occu-
pied more than 5% of the whole tumor area (Fig. 5).
PD-L1 expression in pT1-pT4 tumours
T test for independent 
samples, p = 0.0001 
 Average        
Average + 2Std error    
Average + 0,95*Std dev
Expression on IECs [%]
Over 5 Up to 5
E
x
p
re
s
s
io
n
 o
n
 I
E
C
s
 [
%
] 
50
40
30
20
10
0
n = 90
n = 20
Figure 5. The average extent of PD-L1 expression in tumor 
cells is at least 5 times as high in tumors in which PD-
L1 + immune cells occupy over 5% of their surface area
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may confer them protection from the immune system. 
The macrophages remove debris of tumor cells which 
in effect leads to high levels of tumor antigens in them 
which may result in them being targeted by IECs. PD-
L1 expression on the surface of macrophages may 
protect them against this autoimmune response [37, 
38]. Thus, a parallel increase of PD-L1 expression in 
immune and tumor cells suggests a mechanism in 
which the immune system tries to activate a protective 
mechanism for its own effector cells. Ottenhof et al. in 
their study on the prognostic value of PD-L1 expression 
in penile cancer discovered an association between the 
dispersed pattern of ligand expression in tumor cells 
and a lower probability of survival [39]. In our study, 
the probability of survival in patients with UBC in stages 
pT1-T4 was reduced twice with a dispersed distribution 
of PD-L1+ IECs (Fig. 4). The findings we obtained 
suggest that the effectiveness of immune checkpoints 
linked to PD-L1 expression on IECs dispersed within 
the tumor is higher in comparison with PD-L1 located 
on aggregated IECs in UBC. Pichler et al. concluded 
that outcome prediction in UBC is most effective when 
the expression of PD-L1 on IECs is assessed. Their 
studies indicated, however, that high heterogeneity of 
expression dependent on the type of cells expressing 
PD-L1 cells may lead to unreliable results [40]. Recent 
studies suggest that not only the level of PD-L1 ex-
pression in IECs may have a prognostic value but 
also their location and aggregation within the tumor 
may significantly affect survival [41, 42]. Our findings 
indicate that there is a significant prognostic value 
of assessing the dispersed and aggregated patterns 
of distribution of PD-L1+ IECs within the tumor. The 
diagnostic assessment standards for UBC proposed 
by other authors do not include the assessment of the 
distribution of PD-L1+ IECs within the tumor [25]. In 
our opinion, dispersion or aggregation of immunocom-
petent cells may be an indication of the status of the 
immune system and as such should be included in the 
eligibility criteria for immunotherapy in UBC. 
Conclusions
The assessment of PD-L1 expression in TCs allows 
for prognostic stratification of patients with UBC in all 
stages. The predominance of dispersed or aggregated 
type of distribution of PD-L1+ IECs in the tumor may be 
considered as a new prognostic factor in pT1-pT4 UBC 
and may also indicate the status of the immune system 
of a patient. The assessment of the PD-L1 expression 
in TCs and IECs as well as of the type of distribution 
of IECs PD-L1+ in the tumor should be considered for 
inclusion in immunotherapy eligibility criteria in patients 
with UBC.
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